Baseline Metabolic Tumor Volume Predicts Prognosis of Follicular Lymphoma

Share this content:
Total metabolic tumor volume is effective for determining the prognosis of high-tumor-burden follicular lymphoma.
Total metabolic tumor volume is effective for determining the prognosis of high-tumor-burden follicular lymphoma.

Total metabolic tumor volume is effective for determining the prognosis of high-tumor-burden follicular lymphoma, according to an article published in the Journal of Clinical Oncology.1

Researchers analyzed data from 3 prospective trials containing baseline data of 185 enrolled patients receiving immunochemotherapy. The median age of enrolled patients was 55 years; 92% had stage III or IV follicular lymphoma.

Five-year overall progression-free survival was 55%; overall survival was 92%. Survival was inferior for patients with a total metabolic tumor volume of greater than 510 cm3; the 29% of patients in this group had a 5-year progression-free survival of 33%, and a 5-year overall survival of 85%.

RELATED: Brentuximab Vedotin + AVD and ISRT Efficacious for Early Stage Hodgkin Lymphoma

The authors conclude that baseline total metabolic tumor volume is a strong independent prognostic tool, though if used in conjunction with the Follicular Lymphoma International Prognostic Index, patients at high risk of early progression can be identified.

Reference

  1. Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a tooled analysis of three multicenter studies. J Clin Oncol. 2016 Aug 22. doi: 10.1200/JCO.2016.66.9440 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters